Can Adenosine Fight COVID-19 Acute Respiratory Distress Syndrome?

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Sep 24

PMID 32967358

Citations 18

Authors

Carmela Falcone

Massimo Caracciolo

Pierpaolo Correale

Sebastiano Macheda

Eugenio Giuseppe Vadala

Stefano La Scala

Marco Tescione

Roberta Danieli

Anna Ferrarelli

Maria Grazia Tarsitano

Lorenzo Romano

Antonino De Lorenzo

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease 2019 (COVID-19) patients can develop interstitial pneumonia, which, in turn, can evolve into acute respiratory distress syndrome (ARDS). This is accompanied by an inflammatory cytokine storm. severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has proteins capable of promoting the cytokine storm, especially in patients with comorbidities, including obesity. Since currently no resolutive therapy for ARDS has been found and given the scientific literature regarding the use of adenosine, its application has been hypothesized. Through its receptors, adenosine is able to inhibit the acute inflammatory process, increase the protection capacity of the epithelial barrier, and reduce the damage due to an overactivation of the immune system, such as that occurring in cytokine storms. These features are known in ischemia/reperfusion models and could also be exploited in acute lung injury with hypoxia. Considering these hypotheses, a COVID-19 patient with unresponsive respiratory failure was treated with adenosine for compassionate use. The results showed a rapid improvement of clinical conditions, with negativity of SARS-CoV2 detection.

Citing Articles

Interventional treatments for low back pain due to sacroiliac joint dysfunction: a systematic review of the literature.

De Salvatore S, Russo F, Vadala G, Pascarella G, Papalia G, Ambrosio L Eur Spine J. 2024; 33(4):1407-1423.

PMID: 38329572 DOI: 10.1007/s00586-024-08130-y.

An interaction-based drug discovery screen explains known SARS-CoV-2 inhibitors and predicts new compound scaffolds.

Schake P, Dishnica K, Kaiser F, Leberecht C, Haupt V, Schroeder M Sci Rep. 2023; 13(1):9204.

PMID: 37280244 PMC: 10243268. DOI: 10.1038/s41598-023-35671-x.

Safety of Adenosine for the Treatment of Supraventricular Tachycardia in Hospitalized Patients with COVID-19 Pneumonia.

Zivan T, Ruiz R, Martinez A, Pavri B J Clin Med. 2023; 12(3).

PMID: 36769617 PMC: 9917992. DOI: 10.3390/jcm12030969.

Gain- and Loss-of-Function Alleles Are Associated with COVID-19 Clinical Outcomes.

Baldassarri M, Zguro K, Tomati V, Pastorino C, Fava F, Croci S Cells. 2022; 11(24).

PMID: 36552859 PMC: 9776607. DOI: 10.3390/cells11244096.

Reduces Expression of the SARS-CoV-2 Receptors ACE2 and TMPRSS2.

Sun T, Huang W, Sun Y, Deng J, Chien L, Chou Y Int J Mol Sci. 2022; 23(23).

PMID: 36499094 PMC: 9740160. DOI: 10.3390/ijms232314766.

References

Reutershan J, Vollmer I, Stark S, Wagner R, Ngamsri K, Eltzschig H . Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J. 2008; 23(2):473-82. DOI: 10.1096/fj.08-119701. View

Richardson S, Hirsch J, Narasimhan M, Crawford J, McGinn T, Davidson K . Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020; 323(20):2052-2059. PMC: 7177629. DOI: 10.1001/jama.2020.6775. View

Yang D, Zhang Y, Nguyen H, Koupenova M, Chauhan A, Makitalo M . The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest. 2006; 116(7):1913-23. PMC: 1483170. DOI: 10.1172/JCI27933. View

Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A . High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity (Silver Spring). 2020; 28(7):1195-1199. PMC: 7262326. DOI: 10.1002/oby.22831. View

Chen H, Yang D, Carroll S, Eltzschig H, Ravid K . Activation of the macrophage A2b adenosine receptor regulates tumor necrosis factor-alpha levels following vascular injury. Exp Hematol. 2009; 37(5):533-8. PMC: 5748295. DOI: 10.1016/j.exphem.2009.02.001. View

Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema K . Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018; 14(8):1435-1455. PMC: 6103682. DOI: 10.1080/15548627.2018.1474314. View

Caracciolo M, Macheda S, Labate D, Tescione M, La Scala S, Vadala E . Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome. Front Immunol. 2020; 11:1942. PMC: 7477112. DOI: 10.3389/fimmu.2020.01942. View

Cushley M, Tattersfield A, Holgate S . Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. 1983. Br J Clin Pharmacol. 2004; 58(7):S751-5. PMC: 1884685. DOI: 10.1111/j.1365-2125.2004.02285.x. View

Channappanavar R, Fehr A, Zheng J, Wohlford-Lenane C, Abrahante J, Mack M . IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019; 129(9):3625-3639. PMC: 6715373. DOI: 10.1172/JCI126363. View

10.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

11.

. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. Eur J Intern Med. 2020; 82:38-47. PMC: 7446618. DOI: 10.1016/j.ejim.2020.08.019. View

12.

Eltzschig H, Eckle T . Ischemia and reperfusion--from mechanism to translation. Nat Med. 2011; 17(11):1391-401. PMC: 3886192. DOI: 10.1038/nm.2507. View

13.

Blackburn M, Lee C, Young H, Zhu Z, Chunn J, Kang M . Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway. J Clin Invest. 2003; 112(3):332-44. PMC: 166289. DOI: 10.1172/JCI16815. View

14.

Le T, Berg N, Harting M, Li X, Eltzschig H, Yuan X . Purinergic Signaling in Pulmonary Inflammation. Front Immunol. 2019; 10:1633. PMC: 6646739. DOI: 10.3389/fimmu.2019.01633. View

15.

Stefan N, Birkenfeld A, Schulze M, Ludwig D . Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020; 16(7):341-342. PMC: 7187148. DOI: 10.1038/s41574-020-0364-6. View

16.

Spicuzza L, Di Maria G, Polosa R . Adenosine in the airways: implications and applications. Eur J Pharmacol. 2006; 533(1-3):77-88. DOI: 10.1016/j.ejphar.2005.12.056. View

17.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

18.

Reutershan J, Cagnina R, Chang D, Linden J, Ley K . Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury. J Immunol. 2007; 179(2):1254-63. DOI: 10.4049/jimmunol.179.2.1254. View

19.

Bonneau O, Wyss D, Ferretti S, Blaydon C, Stevenson C, Trifilieff A . Effect of adenosine A2A receptor activation in murine models of respiratory disorders. Am J Physiol Lung Cell Mol Physiol. 2005; 290(5):L1036-43. DOI: 10.1152/ajplung.00422.2005. View

20.

Riva A, Conti F, Bernacchia D, Pezzati L, Sollima S, Merli S . Darunavir does not prevent SARS-CoV-2 infection in HIV patients. Pharmacol Res. 2020; 157:104826. PMC: 7194792. DOI: 10.1016/j.phrs.2020.104826. View